Heron Therapeutics, Inc.   (NASDAQ:HRTX) Analytical Analysis


Quarterly Sales and EPS Roundup:

Heron Therapeutics, Inc.   (NASDAQ:HRTX) reported sales (ttm) of 0, whereas, 9 number of analysts estimated the mean sale of 2.6 million. The analysts estimated sales for the higher end at 6.4 million and lower end at 0 million while the year ago reported sale was 26.44 million.

3 number of analysts have estimated the sales of the company for the quarter ending Feb 17, 2017- Feb 21, 2017, analysts estimated mean sale target of 5.25 million while high and low sale targets are estimated at 8 million and 2.16 million respectively.

Heron Therapeutics, Inc.   (NASDAQ:HRTX) reported earning per shares for the quarter ending Nov 07 BMO at -1.24, whereas, 9 number of analysts estimated the mean EPS at -1.15. The analysts estimated EPS for the higher end at -0.82 and lower end at -1.49 while the year ago reported earnings per share was -0.58.

The company has mean EPS estimate of -0.96 reported by 3 number of analyst for the quarter ending Feb 17, 2017- Feb 21, 2017. The analysts estimated mean EPS at -0.96 while the high and low EPS estimate stand at -0.75 and -1.12 respectively. In contrast to the year ago quarter EPS was at 0. EPS long term mean growth rate estimated by 1 analysts is at 138%, whereas, the high and low Long term growth rate estimated at 138 and 138.

Valuation Ratios of Heron Therapeutics, Inc.   (NASDAQ:HRTX) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Heron Therapeutics, Inc.   (NASDAQ:HRTX). These ratios are important while doing valuation of the company or the shares of the company.

Heron Therapeutics, Inc.   (NASDAQ:HRTX) currently has P/E (Price to Earnings) ratio of 0 while the company’s industry has 42.21 P/E and the sector P/E is 29.87. Similarly, the company’s last 5 years high P/E ratio is 0 and low P/E is 0, whereas, the industry’s and sector’s  high P/E for the past year is 130.71 and 43.94 respectively and low P/E ratio for the last 5 years is 71.17 for the industry and 19.95 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, 38 has Beta of 1.75 while its industry and Sector’s beta remains at 0.79 and 0.83 respectively.

Price to Sale ratio of 38 stands at 0 while Price to Book Ratio stands at 39.23. Its Price to Cash Flow ratio shows the value of 0, whereas, the industry and sector ratio of Price to Cash Flow ticked at 27.02 and 22.64 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Heron Therapeutics, Inc.   (NASDAQ:HRTX) stands at 0 while the industry’s and the sector’s growth for next 5 years ticked at 20.54 and 10.88 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 0 and 69.34.

Heron Therapeutics, Inc.   (NASDAQ:HRTX) Trading Statistics:

The company declined -2.96% and closed its last trading session at $15.2. The market capitalization of the company is at $578.05 Million. The stock currently has Weekly Volatility of 7.50% and Monthly Volatility of 6.86%. The Beta for the company stands at 1.72 and its Average True Range (ATR) shows a value of 1.11.